Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 911 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven... February 10, 2021 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... September 22, 2021 Only a Quarter of Phase III Studies Demonstrated Improved QoL in... July 18, 2022 Load more HOT NEWS Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. Severe mental illness linked to low attendance at cancer screening Eight Factors May Link Disparities in Cancer Death Rates and Income News digest – cancer blood test, gum disease and junk food...
